Postdiagnostic statin use lowers prostate cancer mortality

This article originally appeared here.
Postdiagnostic Statin Use Cuts Mortality in Prostate Cancer
Postdiagnostic Statin Use Cuts Mortality in Prostate Cancer

(HealthDay News) -- For men with prostate cancer, postdiagnostic statin use is associated with a decreased risk of prostate cancer and all-cause mortality, with stronger effects seen for those who used statins before diagnosis, according to a study published online Nov. 4 in the Journal of Clinical Oncology.

In a cohort of 11,772 men newly diagnosed with non-metastatic prostate cancer, Oriana Yu, Ph.D., from the Jewish General Hospital in Montreal, and colleagues examined the correlation between use of statins after a prostate cancer diagnosis and the risk of cancer-related and all-cause mortality.

During a mean follow-up of 4.4 years, the researchers identified 3,499 deaths, including 1,791 prostate cancer-related deaths. The risks of prostate cancer mortality and all-cause mortality were significantly decreased with postdiagnostic statin use (hazard ratios, 0.76 and 0.86, respectively). For patients who also used statins before diagnosis, these decreased risks were more pronounced (hazard ratios, 0.55 and 0.66, respectively), while weaker effects were seen for patients who started statin treatment after diagnosis (hazard ratios, 0.82 and 0.91, respectively).

"In summary, the results of this study indicate that the use of statins after a prostate cancer diagnosis is associated with a decreased risk of cancer-related mortality and all-cause mortality," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Full Text

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs